Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma

被引:94
作者
Choi, C
Witzens, M
Bucur, M
Feuerer, M
Sommerfeldt, N
Trojan, A
Ho, A
Schirrmacher, V
Goldschmidt, H
Beckhove, P
机构
[1] German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany
[2] Univ Heidelberg Hosp, Dept Hematol & Oncol, Heidelberg, Germany
[3] Humboldt Univ, Med Clin, Charite, Dept Expt Rheumatol, Berlin, Germany
[4] Univ Zurich Hosp, Dept Oncol, Zurich, Switzerland
关键词
D O I
10.1182/blood-2004-01-0366
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) is one of the most common hematologic malignancies. Despite extensive therapeutical approaches, cures remain rare exceptions. An important issue for future immunologic treatments is the characterization of appropriate tumor-associated antigens. Recently, a highly glycosylated mucin MUC1 was detected on a majority of multiple myeloma cell lines. We analyzed bone marrow and peripheral blood of 68 patients with HLA-A2-positive myeloma for the presence and functional activity of CD8 T cells specific for the MUC1-derived peptide LLLLTVLTV. Forty-four percent of the patients with MM contained elevated frequencies of MUC1-specific CD8 T cells in freshly isolated samples from peripheral blood (PB) or bone marrow (BM) compared with corresponding samples from healthy donors. BM-residing T cells possessed a higher functional capacity upon specific reactivation than PB-derived T cells with regard to interferon gamma (IFN-gamma) secretion, perforin production, and cytotoxicity. (C) 2005 by The American Society of Hematology
引用
收藏
页码:2132 / 2134
页数:3
相关论文
共 26 条
[1]  
Bai L, 2002, INT J ONCOL, V20, P247
[2]   Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients:: Bidirectional cell stimulation, survival and antitumor activity in vivo [J].
Bai, LH ;
Beckhove, P ;
Feuerer, M ;
Umansky, V ;
Choi, C ;
Solomayer, FSEF ;
Diel, IJ ;
Schirrmacher, V .
INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (01) :73-83
[3]   High-dose therapy and immunomodulatory drugs in multiple myeloma [J].
Barlogie, B ;
Shaughnessy, J ;
Zangari, M ;
Tricot, G .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :26-33
[4]   Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[5]  
Brossart P, 2001, CANCER RES, V61, P6846
[6]   The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma [J].
Brown, RD ;
Yuen, E ;
Nelson, M ;
Gibson, J ;
Joshua, D .
LEUKEMIA, 1997, 11 (08) :1312-1317
[7]   Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy [J].
Dhodapkar, MV ;
Krasovsky, J ;
Osman, K ;
Geller, MD .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (11) :1753-1757
[8]   T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells [J].
Dhodapkar, MV ;
Krasovsky, J ;
Olson, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :13009-13013
[9]   A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma [J].
Dhodapkar, MV ;
Geller, MD ;
Chang, DH ;
Shimizu, K ;
Fujii, SI ;
Dhodapkar, KM ;
Krasovsky, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (12) :1667-1676
[10]   Bone marrow as a priming site for T-cell responses to blood-borne antigen [J].
Feuerer, M ;
Beckhove, P ;
Garbi, N ;
Mahnke, Y ;
Limmer, A ;
Hommel, M ;
Hämmerling, GJ ;
Kyewski, B ;
Hamann, A ;
Umansky, V ;
Schirrmacher, V .
NATURE MEDICINE, 2003, 9 (09) :1151-1157